Stance Capital’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-100
Closed -$6.74K – 335
2026
Q2
$6.74K Sell
100
-599
-86% -$39.9K ﹤0.01% 294
2026
Q1
$43.9K Buy
+699
New +$48.7K 0.02% 153
2025
Q4
– Sell
-666
Closed -$44.8K – 179
2025
Q3
$44.8K Buy
+666
New +$52.7K 0.02% 187

Other funds holding DXCM

Stance Capital's DXCM Position: Q3 2026 in Review

Stance Capital sold out of DexCom (DXCM) in Q3 2026, closing a stake of 100 shares — an estimated $6.74K sold.

Stance Capital first reported a position in DXCM in Q3 2025 and held it in 3 quarters. The position peaked at $44.8K in Q3 2025. 1,056 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

  • Stance Capital reported no remaining DexCom position as of Q3 2026 after selling out during the quarter.
  • Stance Capital sold 100 DexCom shares in Q3 2026, an estimated $6.74K.
  • Stance Capital first reported a position in DexCom in Q3 2025 and held it in 3 quarters.
  • Stance Capital's DexCom position peaked at $44.8K in Q3 2025.
  • 1,056 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on Stance Capital's 13F filing for Q3 2026, filed 16 Nov 2026.